ResearcherChiba Cancer CenterNo recent work listed
Emiri Kita
Matched on ORCID iD 0000-0001-5359-0102; OpenAlex author ID A5078243976. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 5
2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 1 paper
Papers 3
- Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer. Co-author DOI 10.1038/s41598-019-52486-x↗
- Phase II study of induction gemcitabine and S-1 followed by chemoradiotherapy and systemic chemotherapy using S-1 for locally advanced pancreatic cancer. Co-author DOI 10.1007/s00280-017-3350-5↗
- A case of needle tract seeding after EUS-guided FNA in pancreatic cancer, detected by serial positron emission tomography/CT. Co-author DOI 10.1016/j.gie.2016.01.060↗
Closest collaborators
The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Taketo Yamaguchi · 3 shared papers, 2016–2019 · strength 0.28
- Paper Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer. DOI 10.1038/s41598-019-52486-x↗
- Paper A case of needle tract seeding after EUS-guided FNA in pancreatic cancer, detected by serial positron emission tomograp… DOI 10.1016/j.gie.2016.01.060↗
- Paper Phase II study of induction gemcitabine and S-1 followed by chemoradiotherapy and systemic chemotherapy using S-1 for l… DOI 10.1007/s00280-017-3350-5↗
- Kentaro Sudo · 3 shared papers, 2016–2019 · strength 0.28
- Paper Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer. DOI 10.1038/s41598-019-52486-x↗
- Paper A case of needle tract seeding after EUS-guided FNA in pancreatic cancer, detected by serial positron emission tomograp… DOI 10.1016/j.gie.2016.01.060↗
- Paper Phase II study of induction gemcitabine and S-1 followed by chemoradiotherapy and systemic chemotherapy using S-1 for l… DOI 10.1007/s00280-017-3350-5↗
- Akiko Tsujimoto · 2 shared papers, 2017–2019 · strength 0.18
- Hiroshi Ishii · 1 shared paper, 2019 · strength 0.10
- Wataru Takayama · 1 shared paper, 2019 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.